United States: FDA-Regulated Industries: Plan Now For These Changes In 2016

* This is our second post on the regulatory road ahead for life sciences companies in 2016.  Our first post examined developments in food safety regulation under the Food Safety and Modernization Act.

In our last post, Life Sciences Decoded took a look at  new food industry regulations that will roll out in 2016 under the FDA's Food Safety and Modernization Act. But it's not just the food industry that will need to prepare for a new regulatory landscape and heightened enforcement this year.

Big changes are also in store for the industries of animal health, drug, medical devices and tobacco. Among these, the FDA is expected to continue its scrutiny of animal food safety, ramp up its work in post-approval drug studies and keep a close watch on the evolution of mobile medical devices and e-cigarettes. What follows are some regulatory highlights in each area to keep close tabs on as the year unfolds.

Animal health

Under the newly consolidated Center for Food Safety and Applied Nutrition, the FDA has very specific goals in continuing to ensure a safe food supply, not only for humans but animals, too.  This year, expect an increased regulatory emphasis on the cross-over market (human products to animal products).

Much of the focus will continue to be on food supply chain safety. The FDA is expected to inspect feed supply manufacturers for compliance with its newly promulgated safety standards and practices in accordance with its science-based preventive control standards. These inspections will include both processing facilities and transportation methods. In addition, the FDA will continue to promote its Retail Food Program Standards and continue to monitor how companies manage food contamination and record-keeping processes.

Along with an increased focus on animal food or feed animals, it is fully expected that the agency will continue to look at the use of antibiotics in feed animals and continue to use its administrative new drug application review process to move products to the animal health market.


It is expected that while the Office of Inspector General (OIG) will focus efforts on activities subject to the Drug Supply Security Act, particularly Section 202, the FDA will focus its efforts on continued clinical trials post-approval, as well as on its pharmaceutical quality action plan. The FDA also intends to continue its efforts in patient-focused drug development. Specifically, we can expect to see:

  • Increased oversight of postmarketing studies of approved drugs and increased requirements for postmarketing studies.
  • Continued use of clinical outcomes assessment (COA) and the use of the compendium of COAs to not only influence the development of drugs and drug labels but to assist in drug approvals.
  • A review of the rate at which members in a given drug's supply and manufacturing chain share information and enable drug traceability to ensure that the industry is meeting traceability requirements.
  • Public commentary on the draft Guidance "Safety Assessment for IND Safety Reporting," published in December 2015.
  • Continued focus on sunscreen safety after the Sunscreen Innovation Act of 2014. The FDA published three draft Guidance documents in November 2015 concerned with the accuracy of sunscreen safety and efficacy as part of 586A applications for FDA findings of Generally Recognized As Safe and Effective (or GRASE) for new sunscreen additives or combinations of additives.

Medical devices

The Center for Devices and Radiological Health (CDRH) will continue to closely examine medical devices, software applications and related cybersecurity issues. This will include a continued look at devices such as mobile medical applications. In fact, in an effort to get the year off to an early start, on Jan. 22, 2016, CDRH issued draft guidance on Postmarket Management of Cybersecurity in Medical Devices. The Guidance discusses the FDA's recommendations to the device industry on how to identify and address cybersecurity vulnerabilities for marketed medical devices.

Devices that use software in their applications will be subject to a higher level of scrutiny. Where vulnerabilities are identified, these devices and their sponsors will be required to engage in remediation. Particular areas to watch include:

  • A review of how hospitals and medical device manufacturers secure electronic Protected Health Information and its use over hospital networks;  ensure that processes are in place to proactively plan for security of all patient data and that such processes comply with the Quality System Regulations, in addition to the new Guidance.  
  • Continued evolution of the new GUDID device labeling system and database in response to industry and consumer studies. This includes both industry-facing updates, as well as back-end improvements after a significant outage in the fourth quarter of 2015.
  • A 2.3 percent excise tax applied to medical device companies under the Affordable Care Act was suspended for 2016 and 2017.

If you are interested in this topic, Thompson Coburn will be hosting a webinar on March 16 titled "Medical Mobile Apps: An Overview of the Regulatory Environment."


In 2014, the FDA proposed its "Deeming" rule, which, if finalized, would make many tobacco products (including cigars and e-cigarettes, or vaporizers) subject to the FDA's jurisdiction and, therefore, its tobacco regulations. These regulations would include facilities, product, and ingredient registrations, bans on free samples, labelling requirements, and limits on the kinds of allowable marketing and advertising claims.

However, even through 2015, the Deeming Rule remains only as a proposed rule, despite the FDA's best efforts to advance it. But even with this stalemate, the FDA's Tobacco Center has implemented new regulations affecting tobacco products and their entry into the market as evidenced by the implementation of premarket tobacco applications for new tobacco products. This is a new pathway to market for tobacco products that creates a new regulatory hurdle for the tobacco industry requiring them institute and implement a regulatory strategy for their new products to ensure that they can obtain a favorable review of premarket applications. In addition, the FDA will continue its efforts through 2016 in filing complaints against retailers using No-Tobacco-Sale Order actions.

Time to act

FDA-regulated companies must be doing more than just thinking about the impact of these regulations. Instead, they should be drafting a plan for compliance and thinking through the implementation of these plans. The time is fast-approaching when the FDA will commence inspections and subsequent enforcement actions.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.